Glytec, a leading provider of an AI-based technology platform for diabetes and related conditions, announced it has closed a $36 million growth investment led by Savitr Capital and Hayfin Capital Management.
How the funding will be used: This funding will advance the continued expansion of Glytec’s platform, including its flagship Glucommander SaaS solution, advance the development of innovative new technologies to address the growing global health crisis of diabetes and related co-morbidities, and support the continued rapid response to upcoming CMS quality measures that will hold health systems accountable for inpatient glycemic control.
Problem being addressed: The incidence of diabetes and its associated conditions continues to escalate worldwide, placing a significant burden on healthcare systems, payors, and individual lives. A large percentage of hospitalized patients require insulin therapy to regulate their blood sugar levels during their stay. And many patients each year experience an adverse event in the hospital, leading to hypoglycemia. However, hospitals struggle with glucose management metrics, and most lack an automated method for collecting data on rates of hyperglycemia and hypoglycemia.
What Glytec does: Glytec’s intelligent platform helps healthcare providers deliver precision insulin management and optimize metabolic health outcomes, transforming care delivery for millions. And its flagship product, Glucommander®, is the leading cloud-based SaaS solution for inpatient glycemic management, trusted by 400+ hospitals nationwide to improve patient safety and outcomes, reduce costs, and increase revenue through shorter lengths of stay. With urgent and upcoming CMS measures for glycemic management on the horizon, Glytec’s solutions are more critical than ever for healthcare organizations seeking to deliver quality patient care and maintain regulatory compliance.
KEY QUOTES:
“This investment is a pivotal moment for Glytec, validating our vision of a future where deep data-driven insights empower clinicians to deliver highly individualized and proactive care for diabetes and metabolic conditions. Savitr Capital and Hayfin Capital share our belief in the transformative power of technology to improve patient outcomes and alleviate the burden of complex chronic diseases. This capital will enable us to expand our R&D initiatives, scale our platform, and continue to attract top-tier talent as we revolutionize metabolic healthcare.”
Patrick Cua, CEO of Glytec
“Glytec stands at the intersection of cutting-edge AI and critical healthcare need. Their proven track record with Glucommander® and their broader vision for combining digital technology and AI to help hospitals improve patient care, make Glytec a compelling investment.”
Andrew Midler, Managing Member of Savitr Capital
“We are impressed by Glytec’s robust technology, clinical efficacy, and commitment to improving patient lives. Their platform approach to metabolic health, particularly their success in inpatient glucose management, demonstrates a profound understanding of complex clinical challenges and a scalable solution to address them. We are excited to support Glytec’s continued growth and impact.”
Andrew Merrill, Managing Director of Hayfin Capital Management
